sh.sePublications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
CXCL13: A Prognostic Marker in Multiple Sclerosis
Södertörn University College, School of Life Sciences.
2010 (English)Independent thesis Basic level (degree of Bachelor), 10 credits / 15 HE creditsStudent thesis
Abstract [en]

In the demyelinating autoimmune disease multiple sclerosis (MS) there is a great need for validated prognostic biomarkers that can give information about both prognosis and disease course. So far only clinical parameters have been shown to predict future outcome. CXCL13 is a potent B cell chemoattractant that has been suggested to be a potential biomarker candidate. The aim of this study was to investigate the usefulness of CXCL13 as a prognostic biomarker for MS.

Clinical, paraclinical, laboratory and MRI data about a large group of MS patients and controls were collected. CXCL13 levels in cerebrospinal fluid (CSF) samples from these patients were determined by standard enzymelinked immunosorbent assay (ELISA).

In general CXCL13 were increased in CSF in MS, especially in relapsing-remitting MS during relapses, i.e. with ongoing inflammations in the central nervous system. CXCL13 is a good candidate prognostic marker for MS, since newly diagnosed MS with high CXCL13 levels showed worsened disease course within five years. Most importantly, MS conversion occurred in higher rate in possible MS patients with high concentrations of CXCL13 in CSF, and in a shorter time point. This observation may support an early treatment decision in these patients.

In conclusion, this study provides support for an association between CXCL13 levels in the CSF and later development of disease severity in MS.

Place, publisher, year, edition, pages
2010. , p. 44
Keyword [en]
CXCL13, multiple sclerosis, cerebrospinal fluid, prognostic marker, biomarker
National Category
Biochemistry and Molecular Biology Immunology Neurosciences
Identifiers
URN: urn:nbn:se:sh:diva-3656OAI: oai:DiVA.org:sh-3656DiVA, id: diva2:327057
Presentation
2010-06-10, MD515, Södertörn University, 13:00 (English)
Uppsok
Life Earth Science
Supervisors
Available from: 2010-06-28 Created: 2010-06-28 Last updated: 2018-01-12Bibliographically approved

Open Access in DiVA

Carolina Havervall_CXCL13: A Prognostic Marker in Multiple Sclerosis(238 kB)355 downloads
File information
File name FULLTEXT01.pdfFile size 238 kBChecksum SHA-512
985a8101f2edeff802a65f199c6a8ce319061c80dbc2374048f44ff6006132ba8fc369aeeb82d9a4347f6f3d7f42e607daa124d9c390f24e63364584e06fbba2
Type fulltextMimetype application/pdf

By organisation
School of Life Sciences
Biochemistry and Molecular BiologyImmunologyNeurosciences

Search outside of DiVA

GoogleGoogle Scholar
Total: 355 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

urn-nbn

Altmetric score

urn-nbn
Total: 225 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf